Effectiveness of Live Zoster Vaccine Wanes Over Time
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 11, 2023 -- Live zoster vaccination is initially effective against outcomes, including herpes zoster and admission for herpes zoster, but the effectiveness wanes over time, according to a study published online Nov. 8 in The BMJ.
Nicola P. Klein, M.D., PhD., from the Kaiser Permanente Study Center in Oakland, California, and colleagues examined the effectiveness of the live zoster vaccine during more than 10 years after vaccination in a real-world cohort study involving more than 1.5 million people aged 50 years and older followed for almost 9.4 million person-years.
Overall, 34 percent of the 1,505,647 people were vaccinated with live zoster vaccine. The researchers found that among 75,135 incident herpes zoster cases, 7 and 6 percent developed postherpetic neuralgia and had herpes zoster ophthalmicus, respectively, and 0.7 percent were admitted to the hospital for herpes zoster. Vaccine effectiveness was highest in the first year after vaccination for each outcome and decreased considerably over time. Vaccine effectiveness against herpes zoster waned from 67 percent in the first year to 15 percent after 10 years. Effectiveness against postherpetic neuralgia, herpes zoster ophthalmicus, and admission for herpes zoster waned from 83 to 41 percent, 71 to 29 percent, and 90 to 53 percent, respectively, during five to less than eight years. Overall vaccine effectiveness across all follow-up time was 46, 62, 45, and 66 percent against herpes zoster, postherpetic neuralgia, herpes zoster ophthalmicus, and admission for herpes zoster, respectively.
"We found that live zoster vaccine conferred much protection initially but protection waned substantially over time," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Merck, the manufacturer of the vaccine and sponsor of the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
At-School Vaccination Boosts HPV Vaccination Coverage
THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...
Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions
TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...
SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk
TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.